Loading...
Market
FTC conclusion on Teva investigation by end of 2024?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
Official FTC announcements, major news outlets like Washington Post, Reuters
Story
FTC Opens Investigation Into Teva Over Asthma, COPD Patent Listings - Washington Post
Jul 1, 2024, 02:39 PM
The US Federal Trade Commission (FTC) has opened an investigation into Teva Pharmaceutical Industries Ltd., as reported by the Washington Post. The investigation focuses on the company's refusal to remove certain patents for asthma and COPD inhalers from a key federal registry. This move escalates the Democrats' fight with the pharmaceutical industry over what the FTC refers to as 'junk patent listings.' The investigation is part of a broader effort to address antitrust concerns within the pharma sector. Kevin Noonan of the McDonnell Boehnen Hulbert & Berghoff law firm commented on the situation, indicating heightened scrutiny on Teva.
View original story
Similar markets
Fine upheld • 25%
Fine reduced • 25%
Fine overturned • 25%
Appeal withdrawn • 25%
Fines imposed • 25%
Regulations introduced • 25%
No action taken • 25%
Other • 25%
No action taken • 25%
Warnings issued • 25%
Fines imposed • 25%
New regulations proposed • 25%
Appeal successful • 25%
Appeal unsuccessful • 25%
Appeal withdrawn • 25%
No decision by end of 2024 • 25%
Fines imposed • 25%
Regulations introduced • 25%
No action taken • 25%
Other • 25%
Express Scripts wins • 25%
FTC wins • 25%
Settlement reached • 25%
Case dismissed • 25%